Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Omnicell Inc (OMCL)

Omnicell Inc (OMCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,278,037
  • Shares Outstanding, K 45,923
  • Annual Sales, $ 1,147 M
  • Annual Income, $ -20,370 K
  • 60-Month Beta 0.76
  • Price/Sales 1.09
  • Price/Cash Flow 8.67
  • Price/Book 1.04
Trade OMCL with:

Options Overview Details

View History
  • Implied Volatility 68.51% ( -12.89%)
  • Historical Volatility 29.80%
  • IV Percentile 87%
  • IV Rank 57.30%
  • IV High 94.83% on 04/16/24
  • IV Low 33.18% on 09/11/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 117
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 1,203
  • Open Int (30-Day) 1,391

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.35
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -358.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.14 +7.80%
on 04/17/24
29.70 -5.13%
on 03/28/24
+0.25 (+0.90%)
since 03/22/24
3-Month
25.69 +9.69%
on 03/04/24
35.56 -20.75%
on 01/26/24
-5.75 (-16.95%)
since 01/22/24
52-Week
25.69 +9.69%
on 03/04/24
77.14 -63.47%
on 06/07/23
-34.07 (-54.73%)
since 04/21/23

Most Recent Stories

More News
Omnicell: Q4 Earnings Snapshot

Omnicell: Q4 Earnings Snapshot

OMCL : 28.18 (+1.26%)
Omnicell: Q3 Earnings Snapshot

Omnicell: Q3 Earnings Snapshot

OMCL : 28.18 (+1.26%)
Omnicell: Q2 Earnings Snapshot

Omnicell: Q2 Earnings Snapshot

OMCL : 28.18 (+1.26%)
EmpiRx Health Names Healthcare and Technology Veteran Danny Sanchez as CEO

/PRNewswire/ -- EmpiRx Health, the industry's only value-based PBM, today announced that the company's president, Danny Sanchez, has been named Chief Executive...

OMCL : 28.18 (+1.26%)
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

JNJ : 149.12 (+0.82%)
ISRG : 368.93 (+0.71%)
EW : 86.96 (+1.19%)
OMCL : 28.18 (+1.26%)
Omnicell to Present at the BofA Securities 2023 Healthcare Conference

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, announced that it will present at the BofA Securities 2023 Healthcare Conference...

OMCL : 28.18 (+1.26%)
Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up

Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.

OMCL : 28.18 (+1.26%)
IDXX : 479.57 (+0.68%)
ZBH : 120.78 (+1.13%)
EHC : 80.33 (+1.40%)
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

OMCL : 28.18 (+1.26%)
JNJ : 149.12 (+0.82%)
ISRG : 368.93 (+0.71%)
EW : 86.96 (+1.19%)
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 457.14% and 4.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OMCL : 28.18 (+1.26%)
NVTA : 0.0195 (+2.63%)
Omnicell: Q1 Earnings Snapshot

Omnicell: Q1 Earnings Snapshot

OMCL : 28.18 (+1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution,...

See More

Key Turning Points

3rd Resistance Point 29.43
2nd Resistance Point 28.87
1st Resistance Point 28.52
Last Price 28.18
1st Support Level 27.61
2nd Support Level 27.05
3rd Support Level 26.70

See More

52-Week High 77.14
Fibonacci 61.8% 57.48
Fibonacci 50% 51.41
Fibonacci 38.2% 45.34
Last Price 28.18
52-Week Low 25.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar